Workflow
花旗：百济神州-长期布局前景良好。百悦泽美国季度销售额超越阿卡替尼和伊布替尼，重申买入
ONCBEIGENE(ONC) 花旗·2025-05-12 03:14

Flash | | Price (07 May 25 16:00) | US232.25∣∣−−−∣−−−∣∣Targetprice∣US232.25 | | --- | --- | | Target price | US345.00 | | Expected share price return | 48.5% | | Expected dividend yield | 0.0% | | Expected total return | 48.5% | | Market Cap | US$23,004M | Yigal Nochomovitz, Ph.D.AC +1-212-816-1441 yigal.nochomovitz@citi.com 07 May 2025 22:56:30 ET │ 10 pages BeiGene (ONC.O) Well-Positioned for The Long Game. Brukinsa Surpasses Calquence & Imbruvica in US Qtrly Sales, Reiterate Buy CITI'S TAKE The transformation to a global, Swiss-domi ...